Kyle Jenne is VP at IONIS PHARMACEUTICALS INC (IONS). They have made 6 open-market trades across 2 companies since 2020, most recently 2026-04-16.
CIK 0001791857
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| IONS | 23,713 | $1.0M |
| AKCA | 52,012 | $945K |
| Total | $2.0M |
Shares reported on the most recent Form 4, priced at the 2026-04-17 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| IONS | SELL | 2026-04-16 | 2026-04-17 | $75.17 | $368K | -0.9% | -4.0% | -27.6% |
| IONS | SELL | 2026-03-10 | 2026-03-11 | $75.85 | $2.8M | -4.7% | +1.2% | +0.3% |
| IONS | SELL | 2026-01-16 | 2026-01-20 | $75.96 | $138K | +7.2% | +7.9% | -2.9% |
| IONS | SELL | 2025-04-16 | 2025-04-17 | $28.36 | $171K | +9.5% | +21.4% | +52.5% |
| AKCA | SELL | 2020-09-22 | 2020-09-24 | $18.12 | $13K | -0.1% | N/A | N/A |
| AKCA | SELL | 2020-03-23 | 2020-03-25 | $11.75 | $9K | +19.9% | +37.0% | +13.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.